Bml , Inc. · TSE:4694
Bml — H1 FY2025 Earnings Presentation
36 slides from Bml's earnings presentation, Nov 7, 2025
Slide 1: Financial Results Presentation for the First Half of Fiscal 2025
BML Inc. Financial Results Presentation for the First Half of Fiscal 2025 November 7, 2025 Kensuke Kondo, President and Representative Director
Slide 2: Contents
Contents Overview of 1H of Fiscal 2025 Progress of the Ninth Medium-Term Management Plan DX Initiatives Full-Year Forecast for FY2025, Shareholder Returns 1
Slide 3: Overview of 1H of Fiscal 2025
Overview of 1H of Fiscal 2025 2
Slide 4: Earnings History in 10 Years
Earnings History in 10 Years Increase in net sales and profit reflecting efforts to acquire new customers and improve profitability Net sales Operating profit (Millions of yen) (Millions of yen) 6.0％ (＞4.0％) growth from FY2024 FY2025 1H 3
Slide 5: Year-on-Year Comparison
Year-on-Year Comparison (Millions of yen) FY2024 FY2025 YoY Change 1H 1H Net sales 71,373 75,628 4,254 6.0% Testing business 68,025 72,197 4,172 6.1% Clinical testing 65,665 69,681 4,016 6.1% Food hygiene 2,360 2,516 156 6.6% Medical informatics 2,622 2,665 43 1.7% Other businesses 726 765 38 5.3% O
Slide 6: Breakdown of Changes in Sales by Business Segment
Breakdown of Changes in Sales by Business Segment Net sales up \4,254m (6.0％) YoY (Millions of yen) +43 +38 +4,016 +156 Medical Other Food hygiene informatics businesses Clinical business business testing business 5
Slide 7: Breakdown of Changes in Operating Profit by Business Segment
Breakdown of Changes in Operating Profit by Business Segment Operating profit up \744m (14.4％) YoY (Millions of yen) +85 -38 +21 -87 +763 Food Medical Other Company- hygiene informatics businesses wide Clinical business business testing business 6
Slide 8: Overview of Clinical Testing Business
Overview of Clinical Testing Business Net sales: \69,681m Up \4,016m (6.1%) YoY Major topics (Millions of yen) ✓ New acquisitions ・Steady acquisition of new customers 64,391 65,665 69,681 ✓ Promotion of price optimization ・Review of unprofitable items and customers ✓ Price fluctuations ・Increase by
Slide 9: Overview of Food Hygiene and Other Testing Business
Overview of Food Hygiene and Other Testing Business Net sales: \2,516m Up \156m (6.6％) YoY Major topics (Millions of yen) ✓ Promoting transaction terms optimization ・Raised unit price of store inspections primarily for major customers 2,360 2,516 2,258 ✓ Food consulting ・Increase in orders notably f
Slide 10: Overview of Medical Informatics (Electronic Patient Chart) Business
Overview of Medical Informatics (Electronic Patient Chart) Business Net sales: \2,665m Up \43m (1.7％) YoY Major topic (Millions of yen) ✓ Replacements ・Steady response to replacement 2,647 2,622 2,665 demand 9
Slide 11: Overview of Other Businesses
Overview of Other Businesses Net sales: \765m Up \38m (5.3％) YoY Major topics (Millions of yen) ✓ Dispensing pharmacy business ・Increase in prescription of high-priced drugs ✓ Site management organization (SMO) 811 services for clinical trials at medical 726 765 institutions ・Increase in the number
Slide 12: Overview of Capital Expenditure and Depreciation
Overview of Capital Expenditure and Depreciation Capital expenditure (Millions of yen) Investment related (5,046) (8,596) (937) to new buildings Depreciation (Millions of yen) 11
Slide 13: Overview of Cash Flow
Overview of Cash Flow (Millions of yen) FY2024 FY2025 YoY YoY 1H 1H Cash flows from operating activities 9,386 11,515 2,129 Cash flows from investing activities (13,380) (4,713) 8,666 Cash flows from financing activities (2,579) (9,196) (6,617) Cash and cash equivalents at end of period 63,765 61,53
Slide 14: Progress of the Ninth Medium-Term Management Plan
Progress of the Ninth Medium-Term Management Plan 13
Slide 15: Vision
Vision ■ Stable sales growth ■ Achieve a rapid increase in revenue through the effects of the new buildings, DX, and price strategies ■ Balance between growth investment and shareholder returns Net sales Net sales \160 \200 billion *Excluding billion COVID-19-related testing Net sales Net sales EBIT
Slide 16: Basic Strategic Frameworks
Basic Strategic Frameworks Expanding sales and Enhanced quality market Enhancing share Promoting the level of standardization service Development of next- Solutions generation laboratories Development Optimizing of high- performance the business tests portfolio Mutual development Improving profitabi
Slide 17: Development of Next-generation Laboratories
Development of Next-generation Laboratories Expanding sales and market Enhancing the level of share Promoting standardization Road map service ■ Phase 1: BCP / environmental measures and testing capacity Development of next- generation laboratories Development of high- Optimizing the business expans
Slide 18: Development of Next-generation Laboratories
Development of Next-generation Laboratories Expanding ■ Extension of testing capacity with completion of the new sales and Enhancing market share Promoting building the level of standardization service Development Progressing as planned in achieving testing capacity of of next- generation laboratori
Slide 19: Improving Profitability
Improving Profitability Expanding ■ Cost reduction through new building construction sales and Steady progress made in cutting \1,000 million of costs market Enhancing share Promoting the level of Standardization service Development across the processes from reception to reporting of next- generatio
Slide 20: Improving Profitability
Improving Profitability Expanding ■ Radically improve the profitability of the clinical testing business sales and market Profitability improvement: Steady progress made toward Enhancing the level of share Promoting Standardization achieving a ¥4,000 million profit improvement service Development of
Slide 21: EBITDA Margin
EBITDA Margin ■ Profitability improvement plan EBITDA margin on the rise after bottoming out in FY2023 Work on profitability improvement and aim to recover the pre-COVID- 19 pandemic level as soon as possible Changes in the EBITDA margin Up 1.6 points COVID-19 pandemic 20
Slide 22: Development of High-Performance Tests
Development of High-Performance Tests Expanding ■ Expansion of genomic testing lineup sales and market Enhancing the level of share Promoting standardization New test items: Started contracting of 35 items (from April 2024) service Aim for net sales of \14.0 billion in FY2028 Development of next- ge
Slide 23: Plan for Capital Investment and Depreciation
Plan for Capital Investment and Depreciation ■ Progressing in line with initial plan Commenced construction of PCL Morioka Laboratory and BML Food Science Sapporo Laboratory However, no significant changes will be made to the capital expenditure and depreciation plans during the concentrated investm
Slide 24: DX Initiatives
DX Initiatives 23
Slide 25: DX Initiatives: B-Label
DX Initiatives Expanding ■ Reduction of delivery-related operation with B-Label sales and market Enhancing share Promoting Progressively promote nationwide deployment the level of standardization service Development of next- generation Number of B-Label specimens increased by 9.4 times laboratories
Slide 26: DX Initiatives: On-line Test Requests
DX Initiatives Expanding ■ Promotion of on-line test requests sales and market Enhancing share Promoting Customers: The work of making requests and the risk of the level of Standardization service Development personal information leaks can be reduced of next- generation BML: Burden of the work in re
Slide 27: DX Initiatives: Invoice Digitization
DX Initiatives Expanding ■ Promotion of invoice digitization sales and market Customers: Invoices can be received promptly, invoice storage Enhancing the level of share Promoting Standardization procedure can be reduced, and the risk of invoice service Development loss can be eliminated of next- gen
Slide 28: Full-Year Forecast for FY2025, Shareholder Returns
Full-Year Forecast for FY2025, Shareholder Returns 27
Slide 29: Full-Year Forecast for FY2025
Full-Year Forecast for FY2025 ■ Initial plan is maintained ■ Forecasting a profit decrease due to increase in new building- related expenses (depreciation) ■ On the other hand, EBITDA to increase by \1.1 billion to \18.0 billion (Millions of yen) FY2025 FY2025 FY2024 Progress forecast YoY Change 1H
Slide 30: Shareholder Returns
Shareholder Returns ■ Return policy in the Ninth Medium-Term Management Plan ・Payout ratio of 60% or higher, and ¥120 or more per share ■ Annual dividend in the fiscal year ending March 31, 2026 is projected at ¥120 per share of ordinary stock (Payout ratio forecast for FYE March 2026: 78.0％) ■ Acqu
Slide 31: Appendix
fra: Oo c ® rok oY <x
Slide 32: ESG Initiatives
ESG Initiatives Social ■ Received “Platinum Kurumin” certification → As part of our efforts to promote Diversity, Equity & Inclusion, we are actively encouraging male employees to take parental leave, providing support to employees returning from childcare leave, and helping employees balance post-
Slide 33: ESG Initiatives: Health and Productivity Management
ESG Initiatives Health and productivity management ■ BML Heath Declaration “Dedication to creating a healthy and cultured society” To realize this corporate philosophy, the BML Group declares its dedication to contribute to the creation of a healthy and cultured society with each and every employee
Slide 34: ESG Initiatives: Health and Productivity KPIs
ESG Initiatives Health and productivity management ■The Company has set KPIs and targets for each under the supervision of occupational physicians, and is working to achieve these targets. Evaluation indicator FY2021 FY2022 FY2023 FY2024 FY2025 Percentage of employees receiving regular health checku
Slide 35: 34
34
Slide 36: Cautions Regarding Use of This Document
Cautions Regarding Use of This Document <Cautions regarding forward-looking statements, etc.> Forward-looking statements contained in this document, such as projections, strategies and plans, are based on the Company’s judgment formed on the basis of various assumptions made at the time of preparati